Please join us for the last Clareity of the Michaelmas term! We have two great presentations coming up. David Orr will explore corporate social responsibility in South Africa’s mining sector, and Zoë Stewart will discuss her research on the use of an ‘artificial pancreas’ to improve glucose control in pregnant women with Type 1 diabetes. As always pizza, snacks, wine, and other drinks provided!
‘Golden Expectations: Corporate Social Responsibility and Governance in South Africa’s Mining Sector’
South Africa has the strictest corporate social responsibility (CSR) legislation in Africa, and mining firms must comply with stringent requirements in order to secure and retain their mining licenses. Despite facing major challenges, mining firms continue to operate in the South African sphere and match and often exceed the CSR obligations demanded by the state to redress the inequalities of apartheid. This is puzzling, for if one imagines a corporation to be a rational, profit-seeking entity, then it would be natural for the company to meet the CSR legislation to retain their license to operate, but it is unexpected that a firm would exceed it.
Understanding this phenomenon forms the crux of this presentation, which explores how mining firms operating in South Africa have responded to the legislated CSR norms and the effect that they have had on both their governance strategies and their engagement/identities with the state and civil society. The presentation will also include the results of my interviews in South Africa earlier this year.
‘Pumps, pancreases, and pregnancy’
Diabetes is the most common condition affecting pregnant women and is associated with a range of complications including congenital malformation, excess feral growth, still birth, preterm birth and more frequent Caesarean sections and admission to neonatal intensive care units. Babies of mothers with diabetes go on to have higher rates of obesity, diabetes and metabolic disease in later life. Type 1 diabetes is the most severe of the diabetes types and even with newer treatments, complication rates have remained consistently high for these women and their babies over the last 4 decades.
We are testing a novel system of automated insulin delivery called the Artificial Pancreas. This system shows early promise of improved glucose control and has the potential to revolutionise diabetes treatment and improve outcomes for mothers and babies.